ReviewAAPS PharmSciTech2026
The isolated perfused lung: a bridge between in vitro and in vivo studies of inhaled medicinal products.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the complex relationship between drug deposition, pulmonary pharmacokinetics, and clinical efficacy is essential to developing effective inhaled therapies. Harnessing formulation physicochemical properties can improve aerodynamic properties and enhance lung retention, yet predictive in vitro and in silico models remain essential for advanced formulation development. A range of in vitro lung epithelial models has been explored to study transepithelial transport. However, these systems often lack physiological complexity. Advanced platforms such as organoids and lung-on-a-chip models attempt to replicate the structural and mechanical features of the lung, though they face limitations in airflow simulation, aerosol characterization, and operational complexity. Consequently, preclinical in vivo rodent studies continue to play a key role due to their ability to capture systemic interactions. However, several challenges remain, particularly in isolating lung-specific pharmacokinetics. The review focuses on the use of the isolated perfused rat lung (IPL), an ex vivo model that emerged as a valuable tool allowing for the direct measurement of pulmonary absorption while minimizing systemic confounding variables. This model supports accurate control of lung dosing and enables evaluation of local metabolism, clearance, and drug retention. The review outlines IPL setup, applications, and its role in supporting the 3Rs principles (Replace, Reduce, Refine) in animal testing. As an innovative tool, IPL enhances the understanding of pulmonary drug behaviour and holds promise for improving inhaled drug development through more ethical and precise preclinical research.
Indexed as
Identifiers
41761031What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.